Tuesday, July 5, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home News

New approach could lead to quicker generation of effective, personalized cancer vaccines

by Medical Finance
in News
PhoreMost and POLARISqb announce a multi-target collaboration to investigate next-generation cancer therapies
9
SHARES
99
VIEWS
Share on FacebookShare on Twitter

Scientists have created a pipeline for identifying, prioritizing and evaluating potential tumor antigens for the fast generation of cancer vaccines, according to a report published today in eLife.

The new approach could help researchers quickly identify tumor-specific antigens recognized by cytotoxic T cells, generating a powerful, durable and highly specific response against an individual’s tumor. This could lead in turn to a quicker and easier way to generate effective, personalized cancer vaccines based on the identified antigens.

For a cancer vaccine to be effective, we need to select target antigens that elicit a strong immune response, are exclusively present on cancer cells and are tailored to an individual’s unique tumor type. However, only a few, if any, of the antigens on a tumor meet those characteristics, making it very difficult to identify and prioritize potentially effective candidates. Our pipeline comprises all the essential steps for the optimal development of a therapeutic cancer vaccine, but which could be carried out much more quickly on an individual patient basis, enabling true personalized therapy.”


Sara Feola, First Author, Postdoctoral Researcher at the ImmunoViroTherapy Lab (IVTLab), University of Helsinki, Finland

“Developing personalized cancer vaccines needs several different technologies working together and working fast,” adds senior author Vincenzo Cerullo, Professor of Biological Drug Development at the University of Helsinki and group leader at IVTLab. “We need fast and reliable methods to identify and prioritize antigens, as well as rapid, inexpensive and feasible approaches to deliver these antigens to patients. During the past six years, we’ve been working on a project supported by the European Research Council (ERC) to make all the pieces of this complex puzzle work together, creating the pipeline that has been partially described in this work.

“Our research, which builds on previous work, involves developing a novel approach to identify tumor-specific antigens from very small samples, creating a novel algorithm to prioritize peptides based on their similarity to pathogen-derived peptides, and building several different plug-and-play technologies to deliver these peptides together with viruses or bacteria that kill cancer cells.”

In the current study, the team began by investigating the antigen landscape of a tumor cell – that is, all the different peptides on the cell surface. They studied a mouse model of colon cancer and used state-of-the-art technologies, such as an immunopeptidomic approach based on mass spectrometry analysis, to explore surface antigens on the cell. This generated a list of thousands of peptide candidates and presented a challenge of how to prioritize them.

The team used two parallel lines of investigation: first, they looked at the relative amounts of the peptides on cancer cells compared with normal cells. This gave them clues as to whether the antigen was truly tumor-specific. Second, they used a software tool previously developed in their lab to identify tumor antigens that are similar to known pathogen antigens, exploiting their potential ability to cause a similar immune response to the pathogen antigens.

Using these methods, the team narrowed their candidate list down from thousands to 26 antigen candidates. They then studied the potential of these antigens further by testing how well they stimulated T cells, and how effectively they bind to an adenoviral vector that would form the basis of the vaccine. All the candidate antigen peptides interacted with the viral vector, but six peptides performed best and were taken forward for further tests.

The next stage was to see whether a vaccine carrying these target antigens could stimulate enough of an immune response to control or halt tumor growth. To test this, the team used mice with colon tumors on their left and right flanks. They then treated one side of the mice with the vaccine coated with each of the candidate peptide antigens. As hoped, they found that vaccines carrying the peptides improved anti-tumor growth in the treated tumor, but one of the vaccines improved anti-tumor growth in the untreated tumors – suggesting that the peptide antigen in this vaccine had mounted a powerful systemic immune response against the tumors.

“We have developed and validated a pipeline that covers for the first time all the stages of personalized cancer vaccine development, starting with isolating peptides from a primary tumor to analyzing them to identify the best candidates,” Cerullo concludes. “This pipeline is currently being validated in human cancer patients under our flagship project on precision cancer medicine, iCAN.

“Together, our findings demonstrate the feasibility of applying the pipeline to generate a tailored cancer vaccine by focusing on the prioritization and selection criteria and adopting quick plug-and-play technology, called PeptiCRAd, through decorating a clinically approved adenovirus vector with the selected peptides. This opens up the possibility of rapidly generating vaccines for clinical use, where effective personalized therapies represent a major goal of successful treatment.”

Source:

Journal reference:

Feola, S., et al. (2022) A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines. eLife. doi.org/10.7554/eLife.71156.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Scrapping many Covid testing measures is a grave mistake, says London Medical Laboratory

Rutgers researchers use roundworms to unravel how cells communicate with one another

by Medical Finance
July 5, 2022
0

Scientists have long puzzled about a critical way that cells communicate with one another, but Rutgers researchers have used a...

Study: Covid-19 social distancing: when less is more. Image Credit: eldar nurkovic/Shutterstock

Effectiveness of social distancing on COVID-19 infections and fatalities

by Medical Finance
July 5, 2022
0

In a recent study posted to the Research Square* preprint server researchers evaluated the effectiveness of social distancing measures adopted...

Researchers show how an important inhibitor binds to the A2A receptor

Researchers show how an important inhibitor binds to the A2A receptor

by Medical Finance
July 5, 2022
0

The A2A receptor regulates how vigorously the innate immune system attacks diseased cells. Researchers at the University of Bonn have...

Study identifies cellular receptors for alphaviruses shared across mosquitoes, humans, and animals

Saliva tests detect SARS-CoV-2 virus more quickly than nasal swabs

by Medical Finance
July 5, 2022
0

Genetic testing of saliva samples identifies the SARS-CoV-2 virus more quickly than testing of nasal swabs. The research is published...

Hospitalization risk high for IBD patients with incomplete COVID-19 vaccinations

New insight into how gut bacteria work to counter intestinal inflammation

by Medical Finance
July 5, 2022
0

Bile acids made by the liver have long been known for their critical role in helping to absorb the food...

Toxin-producing yeast strains may damage the gut of patients with inflammatory bowel disease

Toxin-producing yeast strains may damage the gut of patients with inflammatory bowel disease

by Medical Finance
July 5, 2022
0

Individual Candida albicans yeast strains in the human gut are as different from each other as the humans that carry...

Next Post
Scientists unravel how blood cells mount the first line of defense against viruses

Scientists identify a promising strategy for stopping Ebola virus polymerase

Dog brains can detect speech and show different activity patterns to many languages

Study finds more than 1,000 gene-activation differences between female and male mouse brains

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Study: A Comparison of Symptom Prevalence, Severity and Duration in the SARS-CoV-2 Omicron Versus Delta Variants Among Vaccinated Individuals from the ZOE COVID Study. Image Credit: Dmitry Demidovich/Shutterstock
    Differences in infection with Omicron or Delta SARS-CoV-2 variants among vaccinated population from the UK
  • Study: The Conserved Macrodomain Is a Potential Therapeutic Target for Coronaviruses and Alphaviruses. Image Credit: Design_Cells / Shutterstock
    Macrodomains represent a unique target for pathogens with pandemic potential
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply